Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017087 | 1.00 | MAOB (0.55) | MAOBGID4MAOASCN9A | |
| SCHEMBL31061697 | 1.00 | MAOB (0.55) | MAOBGID4MAOASCN9A | |
| SCHEMBL2017824 | 1.00 | MAOB (0.55) | MAOBGID4MAOASCN9A | |
| SCHEMBL7395180 | 0.87 | MAOB (0.54) | MAOBGID4MAOASCN9A | |
| SCHEMBL3061396 | 0.87 | MAOB (0.54) | MAOBGID4MAOASCN9A | |
| SCHEMBL2014885 | 0.86 | MAOB (0.74) | MAOBMAOASCN9A | |
| SCHEMBL31060712 | 0.86 | MAOB (0.74) | MAOBMAOASCN9A | |
| SCHEMBL963815 | 0.86 | MAOB (0.74) | MAOBMAOASCN9A | |
| SCHEMBL8935315 | 0.86 | ALOX5 (0.57) | MAOBGID4MAOASCN9A | |
| SCHEMBL7396992 | 0.86 | BCHE (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102274517-A | Methods for treatment of parkinson's disease | — | 2011-12-14 | — | — | CN | claimed |
| EP-2070526-A1 | \"Methods for treatment of Parkinson's disease\ | Newron Pharmaceuticals S.p.A. (IT) | 2009-06-17 | — | — | EP | claimed |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-04-26 | — | — | US | claimed |
| CN-1771030-A | Methods of treating Parkinson's disease | NEWRON PHARMACEUTICALS INC (IT) | 2006-05-10 | — | — | CN | claimed |
| EP-1613296-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | Newron Pharmaceuticals S.p.A. (IT) | 2006-01-11 | — | — | EP | claimed |
| WO-2004089353-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2004-10-21 | — | — | WO | claimed |
| US-9492410-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-8901176-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-12-02 | — | — | US | disclosed |
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-02-28 | — | — | US | disclosed |
| US-8283380-B2 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-10-09 | — | — | US | disclosed |
| CN-102274517-A | Methods for treatment of parkinson's disease | — | 2011-12-14 | — | — | CN | disclosed |
| US-20110160308-A1 | Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders | ALCON RESEARCH, LTD. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-04-26 | — | — | US | disclosed |
| CN-1771030-A | Methods of treating Parkinson's disease | NEWRON PHARMACEUTICALS INC (IT) | 2006-05-10 | — | — | CN | disclosed |
| EP-1613296-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | Newron Pharmaceuticals S.p.A. (IT) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089353-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2004-10-21 | — | — | WO | disclosed |
| US-5391577-A | Active on central nervous system; antiepileptic agents | FARMITALIA CARLO ERBA S R L (IT) | 1995-02-21 | — | — | US | disclosed |
| EP-0400495-B1 | N-phenylalkyl substituted alpha-amino carboxamide derivatives and process for their preparation. | ERBA CARLO SPA (IT) | 1993-11-03 | — | — | EP | disclosed |
| US-5236957-A | Antiepileptic agents | FARMITALIA CARLO ERBA SRL (IT) | 1993-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | MAOB, MAOA, SNCA | MAOB 1/4885GID4 2385/4885MAOA 2/4885 |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | MAOB, MAOA, SNCA | MAOB 1/4885GID4 2385/4885MAOA 2/4885 |
| US-20110160308-A1 | Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders | MAOB, MAOA, ALDH1A2 | MAOB 1/4885GID4 1295/4885MAOA 2/4885 |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | MAOB, MAOA, SNCA | MAOB 1/4885GID4 2385/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.